10-Q: Synergy CHC Q2 Profit Soars on License Revenue, Debt Gains

Synergy CHC Corp. reported a significant increase in net income for Q2 2025, driven by new license revenue and substantial gains from debt settlements, despite a decline in product sales.

Summary

• Net income for Q2 2025 surged to $1,473,237, up from $655,186 in Q2 2024, primarily due to a $2,154,522 gain on settlement of loans and new license revenue.
• Total revenue for Q2 2025 increased slightly to $8,134,996 from $8,024,840 in Q2 2024, with product sales decreasing but offset by $1,400,000 in new license revenue.
• For the six months ended June 30, 2025, net income more than doubled to $2,349,501 from $1,235,716 in the prior year period.
• The company refinanced a significant portion of its outstanding debts, including a $10,000,000 cash repayment and a $1,500,000 equity conversion for a loan with Knight Therapeutics.
• A new $17.5 million term loan facility was secured in May 2025, with proceeds used to repay existing debt and provide working capital.
• Working capital improved significantly, moving to a surplus of $12,383,132 as of June 30, 2025.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025.

Sentiment

Score: 7

Explanation: The financial results show significant improvements in net income and EBITDA, largely driven by a non-recurring gain on debt settlement and new license revenue. The improved working capital and successful debt refinancing are strong positives. However, the decline in product sales, increased interest expense, and the critical disclosure of ineffective internal controls and high customer/vendor concentration temper the overall positive sentiment. The company's ability to continue as a going concern is explicitly addressed as no longer a substantial doubt, which is a positive, but the underlying operational challenges (product sales decline) and control weaknesses remain concerns.

Positives

• Net income for the three months ended June 30, 2025, increased by 125% to $1,473,237 from $655,186 in the prior year.
• Net income for the six months ended June 30, 2025, increased by 90% to $2,349,501 from $1,235,716 in the prior year.
• EBITDA for the three months ended June 30, 2025, more than doubled to $3,804,013 from $1,613,056 in the prior year.
• EBITDA for the six months ended June 30, 2025, increased by 67% to $5,783,637 from $3,463,701 in the prior year.
• Achieved a significant gain on settlement of loans of $2,154,522 for the three and six months ended June 30, 2025.
• Gross profit margin improved to 77% for Q2 2025 (from 69% in Q2 2024) and 76% for H1 2025 (from 71% in H1 2024), driven by new license revenue.
• Working capital improved to a surplus of $12,383,132 as of June 30, 2025, from a deficit of $1,124,599 as of December 31, 2024.
• Net cash used in operating activities decreased to $899,731 for the six months ended June 30, 2025, from $1,140,005 in the prior year period.
• Successfully refinanced a significant portion of outstanding debts, including a $10,000,000 cash repayment and a $1,500,000 equity conversion for a loan with Knight Therapeutics.
• Secured a new $17.5 million term loan credit agreement, providing capital for debt repayment and working capital.
• Management explicitly stated that factors alleviate doubts about the company's ability to continue as a going concern.

Negatives

• Product sales decreased to $6,734,996 in Q2 2025 from $8,024,840 in Q2 2024, and to $13,405,530 in H1 2025 from $17,436,703 in H1 2024, primarily due to a non-repeating new product sell-in to one customer in 2024.
• Interest expense significantly increased to $2,107,714 in Q2 2025 from $745,528 in Q2 2024, and to $3,203,083 in H1 2025 from $1,855,508 in H1 2024, due to new loans and share issuance related to debt modification.
• General and administrative expenses increased to $1,519,325 in Q2 2025 from $903,838 in Q2 2024, and to $2,826,039 in H1 2025 from $2,252,223 in H1 2024, primarily due to public market expenses.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, and controls have not been designed to ensure timely communication of material information.
• High concentration of credit risk: two customers accounted for 84% of trade accounts receivable as of June 30, 2025.
• High concentration of revenue: three customers accounted for approximately 80% of net revenue for the six months ended June 30, 2025.
• High concentration of accounts payable: two vendors accounted for 58% of accounts payable as of June 30, 2025.
• A related party loan receivable of $4,427,883 is due by December 31, 2025, with a pledge of borrower's stock as security if not repaid.

Risks

• The company's ability to meet its obligations depends on generating enough cash from operations and other available sources.
• The company has a history of accumulated deficit, totaling $41,750,312 as of June 30, 2025.
• The company has not completed its evaluation of Net Operating Loss (NOL) utilization limitations under Internal Revenue Code Section 382/383, which could limit or eliminate the amount of NOLs that can be utilized each year.
• NOLs attributable to Breakthrough Products, Inc. are Separate Return Limitation Year (SRLY) NOLs, which may generally not be available for use.
• The company has not filed its State & Local Income/Franchise tax returns in states it is required to file, leaving returns and liability open.
• The outcome of litigation is inherently uncertain, and proceedings or claims can have an adverse impact due to defense and settlement costs, diversion of resources, and other factors.
• The company relies on a few major customers and suppliers, creating concentration risk in accounts receivable, revenue, and accounts payable.
• The company's cash deposits at times exceed the federally insured limit of $250,000, exposing it to uninsured balances ($1,286,994 at June 30, 2025).
• The loan receivable from a related party (CEO-controlled company) of $4,427,883 is due by December 31, 2025, and if not repaid, the borrower will pledge shares as security.
• The company's disclosure controls and procedures were not effective, and internal controls over financial reporting have not been designed to ensure timely communication of material information.

Future Outlook

The company plans to organically grow its current product lines by developing and launching new products and expanding into new markets, specifically increasing distribution for its recently launched FOCUSfactor ready-to-drink beverage. It also intends to pursue further strategic acquisitions that align with its brand portfolio.

Management Comments

• We focused on developing our currently owned brands into new markets and by product extensions.
• Our objective is to grow our two targeted verticals (Nutraceuticals and Ready To Drinks (RTDs)) to provide a balanced and synergistic portfolio that drives consumer demand via multiple channels.
• Management concluded that above factors alleviate doubts about the Company's ability to generate enough cash from operations and other available sources to satisfy its obligations for the next twelve months from the issuance date.
• We intend to organically grow our current product lines by developing and launching new products and expanding into new markets.
• We continue to evaluate opportunities and candidates that we believe fit well with our brand portfolio.

Industry Context

Synergy CHC operates in the consumer health and wellness sector, specifically nutraceuticals and ready-to-drink beverages. The company's strategy of organic growth through new product development and market expansion, alongside strategic acquisitions, aligns with broader industry trends of consolidation and diversification within the health and wellness space. The introduction of license revenue indicates a move towards leveraging intellectual property for broader market reach, a common strategy for established brands seeking to expand without direct operational overhead in new territories. The focus on RTDs also reflects a growing consumer preference for convenient, on-the-go health solutions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.
• The significant improvement in gross profit margin (from 69% to 77% in Q2) driven by license revenue suggests a potentially more capital-efficient revenue stream compared to traditional product sales.
• The high customer and vendor concentration, with 80% of H1 2025 revenue from three customers and 58% of accounts payable from two vendors, indicates a higher-than-average concentration risk compared to diversified industry players.
• The disclosure of ineffective internal controls is a notable deviation from best practices for publicly traded companies and could signal operational inefficiencies or compliance risks.

Corporate Governance

Legal Proceedings

• The company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business, with outcomes inherently uncertain and potential adverse impacts from defense/settlement costs or diversion of resources.

Related Party Transactions

• Paid consulting fees to a company owned by CEO Jack Ross (prepaid balance of $695,587 as of June 30, 2025).
• Advanced $398,606 in prepaid consulting fees to CEO's company during H1 2025.
• Received $135,000 in advances from a related party during H1 2025, which was subsequently repaid.
• Paid prepaid rent of $53,720 for one year to a company owned by CEO Jack Ross during Q2 2025.
• Owed $4,427,883 by a related party controlled by the CEO as a loan receivable, due December 31, 2025, with borrower's stock to be pledged as security if not repaid.
• Entered into Sixth Amended Agreement with Knight Therapeutics Inc., a shareholder, to modify prior agreements, consolidating outstanding loans and extending maturity dates to March 31, 2026.
• Repaid $10,000,000 of the August 9, 2017 loan to Knight Therapeutics Inc.
• Converted $1,500,000 of the August 9, 2017 loan to Knight Therapeutics Inc. into equity, issuing pre-funded warrants.
• Owed Knight Therapeutics $90,587 (US Dollars) as of June 30, 2025, for distribution fees and royalties under a 2016 agreement.
• Issued 441,178 shares valued at $847,062 to a lender for releasing CEO Jack Ross from a personal obligation related to a loan.

Stakeholder Impact

• Shareholders: Positive impact from increased net income and EPS, improved working capital, and successful debt refinancing. However, dilution from equity conversion for debt settlement and share issuance for loan modification, along with ineffective internal controls, could be concerns. The related party loan receivable also presents a potential risk.
• Creditors: Improved liquidity and successful refinancing of significant debt obligations reduce immediate credit risk. The new secured term loan provides a clearer repayment structure.
• Employees: No direct impact mentioned, but strategic growth initiatives could imply future opportunities.
• Customers: Product sales decline in nutraceuticals suggests potential shifts in customer demand or competitive pressures, though new license revenue indicates broader market reach. High customer concentration implies reliance on a few key relationships.
• Suppliers: High supplier concentration indicates reliance on a few key relationships, which could pose supply chain risks if those relationships are disrupted.

Next Steps

• Organically grow current product lines by developing and launching new products.
• Expand into new markets.
• Increase distribution for the recently launched FOCUSfactor ready-to-drink beverage.
• Pursue additional strategic acquisitions that fit the brand portfolio.
• Implement restructuring and cost reductions if profitability and cash flow projections trend unfavorably.
• Raise additional capital through line of credit and/or loans financing for future mergers and acquisitions if needed.
• Raise additional capital through an additional capital raise if needed.

Key Dates

Recommendation

While Synergy CHC Corp. demonstrated strong financial performance in Q2 2025 with a significant increase in net income and EBITDA, largely driven by a non-recurring gain on debt settlement and new license revenue, several factors warrant a 'hold' recommendation rather than a 'buy'. The decline in core product sales suggests underlying operational challenges in the primary business segment. The substantial increase in interest expense, despite debt refinancing, indicates higher financing costs. Most critically, the disclosed ineffectiveness of disclosure controls and procedures, coupled with high customer and vendor concentration and a large related-party loan receivable, introduce significant governance and operational risks. The positive shift in working capital and alleviation of going concern doubts are favorable, but the unresolved control weaknesses and reliance on non-recurring gains for profit growth suggest a need for further clarity and demonstrated operational consistency before a stronger recommendation can be made. Investors should monitor the remediation of internal control issues and the sustainability of revenue growth beyond license agreements.

Keywords

Synergy CHC, SNYR, Quarterly Report, SEC Filing, Financial Results, Nutraceuticals, Consumer Health, FOCUSfactor, Flat Tummy, Debt Refinancing, License Revenue, EBITDA, Working Capital, Internal Controls, Risk Factors, Corporate Governance